Collegium Pharmaceutical-Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance

– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of$ 41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of$ 775 to $785 Million and Adjusted EBITDA Guidance in the Range of$ 460 to $470 Million – – Ende ...